Buy Spiriva Respimat cartridge 2.5 mcg/dose, Respimat
  • Buy Spiriva Respimat cartridge 2.5 mcg/dose, Respimat

Spiriva® [Tiotropium bromide]

Boehringer Ingelheim
1554 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Spiriva has an anticholinergic, bronchodilatory effect.


As maintenance therapy for patients with COPD, including chronic bronchitis and emphysema (with persistent dyspnea and to prevent exacerbations).


1 dose contains 2.5 mcg of tiotropium bromide.

Tiotropium bromide is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Spiriva Respimat Boehringer Ingelheim Austria cartridge
Spiriva Boehringer Ingelheim Austria capsules

No customer reviews for the moment.

Write your review

Write your review

Spiriva® [Tiotropium bromide]

Dosage and Administration

The recommended dose of Spiriva Respimat is 2 inhalations (2 breaths) of an aerosol using the Respimat inhalation device.
Inhalation should be carried out 1 time per day at the same time.
Elderly patients can use Spiriva Respimat according to the recommended dose.
In patients with renal insufficiency, Spiriva Respimat may be used according to the recommended dose. The use of Spiriva Respimat, as well as other drugs that are mainly excreted by the kidneys, should be carried out under medical supervision in patients with moderate and severe renal insufficiency. In patients with hepatic insufficiency, the drug can be used according to the recommended dose.

Instructions for use
You should carefully follow these instructions.
Installing the cartridge and its preparation for use
Before first use it is necessary:
1. With the green cap closed, press the fuse and force out the transparent base.
2. Remove the cartridge from the box. Insert the narrow end of the cartridge into the inhaler until it clicks into place. The cartridge must be pressed gently against the hard surface to ensure that it is fully in place. Do not remove the cartridge after it has been installed in the inhaler.
3. Insert the transparent base into place. Do not remove the transparent base again.
To prepare the Spiriva Respimat inhaler for first use:
4. The inhaler Spiriva Respimat is held in its right hand with the green cap closed. Rotate the transparent base in the direction of the red arrows on the label until it clicks (half a turn).
5. Open the green cap until it opens completely.
6. Send the inhaler Spiriwa Respimat down. Press the button to release the dose. Close the green cap.
Repeat steps 4, 5 and 6 until an aerosol appears.
Then repeat 3 times the steps 4, 5 and 6 in order to make sure that the inhaler is ready for use.
Now inhaler Spiriva Respimat is ready for use.
These steps do not affect the number of available doses. After preparation, the inhaler Spiriva Respimat is designed for 30 doses (60 breaths).

Adverse reactions

Many of these adverse effects can be attributed to the anticholinergic properties of Spiriva Respimat.
Criteria for assessing the frequency of adverse drug reactions:> 10% - very often; 1–10% often; 0.1–1% - infrequently; 0.01–0.1% - rarely; On the part of metabolism, metabolism: the frequency is unknown - dehydration.
On the part of the nervous system: infrequently - dizziness; frequency unknown - insomnia.
From the organ of vision: infrequently - blurred vision; rarely - glaucoma, increased intraocular pressure.
Since the cardiovascular system: infrequently - atrial fibrillation, palpitations, supraventricular tachycardia, tachycardia.
On the part of the respiratory system: rarely - cough, nosebleeds, pharyngitis, dysphonia; rarely - bronchospasm, laryngitis; frequency unknown - sinusitis.
From the digestive tract: often - dry mouth, usually moderate; infrequently - constipation, oropharyngeal candidiasis, dysphagia; rarely - GERD, gingivitis, glossitis, stomatitis; frequency is unknown - intestinal obstruction, including paralytic intestinal obstruction.
On the part of the skin and immune system: infrequently - rash, itching; rarely - angioedema, urticaria, skin infections and skin ulcers, dry skin; frequency unknown - hypersensitivity (including immediate-type allergic reactions).
On the part of the musculoskeletal system and connective tissue: the frequency is unknown - swelling of the joints.
From the urinary system: infrequently - urinary retention (usually in predisposed men), urination disorders; rarely, urinary tract infection.


Hypersensitivity (includingto atropine or its derivatives, for example, ipratropium or oxitropium), I trimester of pregnancy, age up to 18 years.

Drug interactions

Despite the fact that special studies of interaction with other drugs were not performed, tiotropium bromide was used simultaneously with other drugs (sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids, which are used in the treatment of COPD) without adverse reactions. The study of the constant simultaneous use of tiotropium bromide with other anticholinergic drugs was not performed. Moreover, the constant simultaneous use of anticholinergic drugs with Spiriva Respimat is not recommended.

Pregnancy and Lactation

There are no clinical data on the safety and efficacy of using Spiriva® Respimat® during pregnancy.
In preclinical studies, no indications of direct or indirect adverse effects on pregnancy, embryo / fetus development, childbirth, or postnatal development have been obtained.
There are no clinical data on the safety and efficacy of tiotropium bromide during breastfeeding.
Spiriva Respimat should not be used in pregnant or lactating women, unless the potential benefit to the mother outweighs the potential risk to the fetus and child. For the period of use of the drug it is necessary to stop breastfeeding.

Special instructions

Spiriva Respimat - bronchodilator, which is prescribed 1 time per day for maintenance therapy. The drug is not intended for the initial treatment of an acute attack of bronchospasm, that is, for emergency care.
Hypersensitivity reactions may occur after using the p-ra for inhalation Spiriva Respimat.
Respiriva Respimat is used with caution in patients with angle-closure glaucoma, prostatic hyperplasia, or bladder neck obstruction.
The use of inhaled drugs may cause bronchospasm caused by their conduct.
There is an increased risk of death in patients with heart rhythm disorders. The relationship of cardiac arrhythmia with death is questionable, in addition, the causal relationship with tiotropium Respimat is not established. The use of Spiriva Respimat, mainly excreted by the kidneys, should be carried out under medical supervision in patients with moderate to severe renal insufficiency (creatinine clearance Patients should be instructed on the correct use of Spiriv Respimat. The solution or aerosol in the eye is unacceptable. Signs of angle-closure glaucoma may pain or discomfort in the eyes, blurred vision, the appearance of a halo or colored spots before the eyes in combination with redness of the eye in the form of conjunctival hyperemia tivy or cornea. If you experience these symptoms in any combination should immediately seek specialized medical attention. Treatment for eye drops that cause constriction of the pupil, is not considered effective.
Spiriva cartridges should be used only with Respimat inhaler.
During pregnancy and breastfeeding. The drug should not be used during pregnancy and lactation without assessing the ratio of the expected benefits and the possible risk to the fetus or child.
Children. The drug Spiriva Respimat not recommended for use in children due to lack of data regarding efficacy and safety.
The ability to influence the reaction rate when driving and working with other mechanisms. For the period of treatment should refrain from driving and working with other mechanisms, given the possibility of dizziness or blurred vision.


The use of the drug Spiriva Respimat in high doses can cause anticholinergic signs and symptoms: dryness of the mucous membranes of the mouth / throat and nasal cavity with a dose-dependent frequency, a decrease in salivary secretions.
Acute intoxication due to accidental oral intake of p-ra tiotropia for inhalations from the cartridge is unlikely due to low bioavailability when administered orally.

  • Brand name: Spiriva Respimat
  • Active ingredient: Tiotropium bromide
  • Dosage form: Powder for inhalation.
  • Manufacturer: Boehringer Ingelheim
  • Country of Origin: Austria

Studies and clinical trials of Tiotropium bromide (Click to expand)

  1. Effects of Spascupreel versus hyoscine butylbromide for gastrointestinal cramps in children
  2. Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy
  3. Effect of tiotropium bromide on expression of CD8+CD25+FoxP3+regulatory T cells in patients with stable chronic obstructive pulmonary disease
  4. Comparative study on the efficacy of tiotropium bromide inhalation and oral doxofylline treatment of moderate to severe stable chronic obstructive pulmonary disease
  5. Plethysmography and impulse oscillometry assessment of tiotropium and ipratropium bromide; a randomized, double-blind, placebo-controlled, cross-over study in healthy subjects
  6. Inhaled tiotropium bromide and risk of stroke
  7. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma
  8. Fresh from the pipeline: Tiotropium bromide
  9. Skin reaction to inhaled tiotropium bromide: a case report
  10. Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled Asthma
  11. Tiotropium bromide: A new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease
  12. Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide
  13. Positive interaction of the novel β2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs
  14. Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD
  15. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore
  16. Effect of tiotropium bromide on the cardiovascular response to exercise in COPD
  17. Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD
  18. Acetylcholine, muscarinic receptors and airway remodeling novel perspectives for tiotropium bromide
  19. Long-acting β2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?
  20. A Rapid, Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Formoterol Fumarate, Tiotropium Bromide, and Ciclesonide in a Pulmonary Drug Produc
  21. Efficacy of Aclidinium Bromide 400 μg Twice Daily Compared With Placebo and Tiotropium in Patients With Moderate to Severe COPD
  22. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease
  24. PRS12 Budget Impact Analysis of Tiotropium Bromide Versus Ipratropium Bromide on the Top of Standard Therapy in the Treatment of Chronic Obstructive Pulmonary Disease (Copd) in Russian Federation

8 other products in the same category: